Literature DB >> 32131814

Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective.

Talemwa Nalugwa1,2, Priya B Shete3,4, Mariam Nantale1,2, Katherine Farr2,5, Christopher Ojok1,2, Emma Ochom1,2, Frank Mugabe6, Moses Joloba6,7, David W Dowdy8, David A J Moore9, J Lucian Davis10,11, Adithya Cattamanchi2,5, Achilles Katamba1,2.   

Abstract

BACKGROUND: Many high burden countries are scaling-up GeneXpert® MTB/RIF (Xpert) testing for tuberculosis (TB) using a hub-and-spoke model. However, the effect of scale up on reducing TB has been limited. We sought to characterize variation in implementation of referral-based Xpert TB testing across Uganda, and to identify health system factors that may enhance or prevent high-quality implementation of Xpert testing services.
METHODS: We conducted a cross-sectional study triangulating quantitative and qualitative data sources at 23 community health centers linked to one of 15 Xpert testing sites between November 2016 and May 2017 to assess health systems infrastructure for hub-and-spoke Xpert testing. Data sources included a standardized site assessment survey, routine TB notification data, and field notes from site visits.
RESULTS: Challenges with Xpert implementation occurred at every step of the diagnostic evaluation process, leading to low overall uptake of testing. Of 2192 patients eligible for TB testing, only 574 (26%) who initiated testing were referred for Xpert testing. Of those, 54 (9.4%) were Xpert confirmed positive just under half initiated treatment within 14 days (n = 25, 46%). Gaps in required infrastructure at 23 community health centers to support the hub-and-spoke system included lack of refrigeration (n = 14, 61%) for sputum testing and lack of telephone/mobile communication (n = 21, 91%). Motorcycle riders responsible for transporting sputum to Xpert sites operated variable with trips once, twice, or three times a week at 10 (43%), nine (39%) and four (17%) health centers, respectively. Staff recorded Xpert results in the TB laboratory register at only one health center and called patients with positive results at only two health centers. Of the 15 Xpert testing sites, five (33%) had at least one non-functioning module. The median number of tests per day was 3.57 (IQR 2.06-4.54), and 10 (67%) sites had error/invalid rates > 5%.
CONCLUSIONS: Although Xpert devices are now widely distributed throughout Uganda, health system factors across the continuum from test referral to results reporting and treatment initiation preclude effective implementation of Xpert testing for patients presenting to peripheral health centers. Support for scale up of innovative technologies should include support for communication, coordination and health systems integration.

Entities:  

Keywords:  Diagnosis; GeneXpert; Health system; Infectious disease; Infrastructure; Tuberculosis

Year:  2020        PMID: 32131814     DOI: 10.1186/s12913-020-4997-x

Source DB:  PubMed          Journal:  BMC Health Serv Res        ISSN: 1472-6963            Impact factor:   2.655


  10 in total

1.  Impact of on-site Xpert on TB diagnosis and mortality trends in Uganda.

Authors:  S Walusimbi; I Najjingo; S Zawedde-Muyanja; J Musaazi; A Nyombi; W Katagira; J Ssendiwala; W Muttamba
Journal:  Public Health Action       Date:  2022-06-21

Review 2.  Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.

Authors:  Nora Engel; Eleanor A Ochodo; Perpetua Wanjiku Karanja; Bey-Marrié Schmidt; Ricky Janssen; Karen R Steingart; Sandy Oliver
Journal:  Cochrane Database Syst Rev       Date:  2022-04-26

3.  Impact of accreditation on health care services performance in Kiryandongo district, Uganda: a longitudinal study.

Authors:  Moses Matovu; Elias Musiime; Patrick Olak; Muhammad Mulindwa; Eve Namisango; Kilian Songwe
Journal:  BMC Health Serv Res       Date:  2022-02-10       Impact factor: 2.655

Review 4.  Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment.

Authors:  Christopher G Shield; Benjamin M C Swift; Timothy D McHugh; Rebekah M Dedrick; Graham F Hatfull; Giovanni Satta
Journal:  Microorganisms       Date:  2021-11-16

5.  Trends of notification rates and treatment outcomes of tuberculosis cases with and without HIV co-infection in eight rural districts of Uganda (2015 - 2019).

Authors:  Joseph Baruch Baluku; Resty Nanyonjo; Jolly Ayo; Jehu Eleazer Obwalatum; Jane Nakaweesi; Catherine Senyimba; Deus Lukoye; Joseph Lubwama; Jennifer Ward; Barbara Mukasa
Journal:  BMC Public Health       Date:  2022-04-05       Impact factor: 3.295

6.  Linkage to care and treatment outcomes for patients diagnosed with drug-susceptible tuberculosis using Xpert MTB/RIF assay in Thaba-Tseka district in Lesotho.

Authors:  Nteseng Mabote; Meseret Mamo; Bienvenu Nsakala; Samson Lanje; Ntumwa R Mwanawabene; Bulemba Katende
Journal:  IJID Reg       Date:  2022-08-30

7.  High Prevalence of Rifampicin Resistance Associated with Rural Residence and Very Low Bacillary Load among TB/HIV-Coinfected Patients at the National Tuberculosis Treatment Center in Uganda.

Authors:  Joseph Baruch Baluku; Pallen Mugabe; Rose Mulwana; Sylvia Nassozi; Richard Katuramu; William Worodria
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

8.  Evaluation of underweight status may improve identification of the highest-risk patients during outpatient evaluation for pulmonary tuberculosis.

Authors:  Peter J Kitonsa; Annet Nalutaaya; James Mukiibi; Olga Nakasolya; David Isooba; Caleb Kamoga; Yeonsoo Baik; Katherine Robsky; David W Dowdy; Achilles Katamba; Emily A Kendall
Journal:  PLoS One       Date:  2020-12-11       Impact factor: 3.752

9.  Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda.

Authors:  Talemwa Nalugwa; Margaret Handley; Priya Shete; Christopher Ojok; Mariam Nantale; Tania Reza; Achilles Katamba; Adithya Cattamanchi; Sara Ackerman
Journal:  Implement Sci Commun       Date:  2022-02-02

Review 10.  Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all?

Authors:  Ruvandhi R Nathavitharana; Alberto L Garcia-Basteiro; Morten Ruhwald; Frank Cobelens; Grant Theron
Journal:  EBioMedicine       Date:  2022-03-23       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.